Rachel Megyesi
Psychiatric/Mental Health · Schenectady, NYNPI 1396008496
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 326 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $4,259, more than ten times the $408 reported in 2022. Among psychiatric/mental health clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 326 payments — averaging $27.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Alkermes, Inc.$1K
- AbbVie$674
- E.r. Squibb & Sons, L.L.C.$573
- plus $2K from 9 others
What the payments were for
- Food & beverage$8,978100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 60 | $1,776 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 70 | $1,690 |
| Otsuka America Pharmaceutical, Inc. | 53 | $1,375 |
| Alkermes, Inc. | 31 | $1,176 |
| AbbVie | 28 | $674 |
| E.r. Squibb & Sons, L.L.C. | 24 | $573 |
| Axsome Therapeutics, Inc. | 13 | $475 |
| Neurocrine Biosciences, Inc. | 11 | $411 |
| Teva Pharmaceuticals USA, Inc. | 18 | $321 |
| Supernus Pharmaceuticals, Inc. | 5 | $221 |
| Lundbeck LLC | 4 | $96 |
| Vanda Pharmaceuticals Inc. | 5 | $96 |
| Indivior Inc. | 2 | $43 |
| Corium, LLC | 1 | $30 |
| Astellas Pharma US Inc | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,978 in reported general payments places this provider in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Duloxetine Hcl | 11 | $342 |
| Mirtazapine | 13 | $318 |
| Hydroxyzine Pamoate | 11 | $167 |
| Quetiapine Fumarate | 16 | $158 |
| Trazodone Hcl | 21 | $103 |
| Clonidine Hcl | 12 | $95 |
| Clonazepam | 11 | $86 |
| Fluoxetine Hcl | 13 | $71 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Schenectady
- Carrie EdickSchenectady$484K
- Ronald OtworiSchenectady$10K
- Tammy RussoNiskayuna$568K
- Eric SpronzCentereach$448K
- Terry Jo Brooks-DevlinTonawanda$176K
- Kevin SiewersStaten Island$155K
- Daniel BreeyearNiskayuna$149K
- Elijah StevensBinghamton$131K
- Kayanna JonasFar Rockaway$93K
- Alexis CrisafiFishkill$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.